Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Group Set To Enter Biosimilars Market With $1.9 Billion Investment

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Samsung Group has ended years of exploration for new business realms beyond its traditional pipeline of semiconductors and electronics products; South Korea's leading conglomerate is set to enter the healthcare sector, particularly biosimilars and medical devices, with an initial investment of roughly $4.1 billion

You may also be interested in...



Korea’s CJ CheilJedang Corp. Under Police Investigation For Rebates

Probes into CJ and Dong-A signal Korea’s anti-rebate stance won’t stop anytime soon.

Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV

Samsung plans to begin construction on its manufacturing plant in Incheon during the first half of this year, and production is expected to commence in the first half of 2013.

Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV

Samsung plans to begin construction on its manufacturing plant in Incheon during the first half of this year, and production is expected to commence in the first half of 2013.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel